Reviva Pharmaceuticals Holdings Inc
revivapharma.comWhat Do They Do?
Develops drug candidates for neuropsychiatric, inflammatory and cardiometabolic diseases, including brilaroxazine for schizophrenia and other conditions.
10-K for FY2025, filed Mar 30, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 30, 2026
Who Are Their Customers?
The company currently has no customers.
10-K for FY2025, filed Mar 30, 2026Sales and MarketingView ↗
How Are They Changing?
-
May 13, 2026
Nasdaq delisting moves the stock to OTCQB
After it failed to regain the minimum bid price requirement, trading on Nasdaq was suspended and the shares moved to OTCQB.
Sources
8-K, filed May 13, 2026
As previously disclosed, the common stock of Reviva Pharmaceuticals Holdings, Inc. (the “Company”) was not in compliance with the…View ↗
Pipeline disease focus
The stated pipeline focus changes from central nervous system, respiratory, and metabolic diseases to central nervous system, inflammatory, and cardiometabolic diseases, while brilaroxazine remains in development for respiratory indications.
10-K for FY2022, filed Mar 30, 2023 10-K for FY2025, filed Mar 30, 2026We are a clinical-stage pharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for…View ↗
Loading...
